SG/CALL/MODERNA/175/0.1/20.12.24 | Market Closed - Euronext Paris 12:30:00 2024-07-12 pm EDT | ||
| 0.735 EUR | +5.76% |
|
| Current month | +49.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.755 | +8.63% |
| 24-07-11 | 0.695 | +20.87% |
| 24-07-10 | 0.575 | +1.77% |
| 24-07-09 | 0.565 | 0.00% |
| 24-07-08 | 0.565 | +11.88% |
Real-time Euronext Paris
Last update July 12, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 73G9S | |
| ISIN | DE000SY166N3 |
| Date issued | 2024-06-24 |
| Strike | 175 $ |
| Maturity | 2024-12-20 (160 Days) |
| Parity | 10 : 1 |
| Emission price | 1.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.01 € |
|---|---|
| Lowest since issue | 0.485 € |
| Spread | 0.01 € |
| Spread % | 1.35% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.12%
- Stock Market
- Warrants
- 73G9S Warrant
